PROSPER

  • Research type

    Research Study

  • Full title

    Psychological therapy Readiness and resourcing in Oncology – Support to Promote an Enhanced Response (PROSPER): a randomised controlled trial

  • IRAS ID

    342394

  • Contact name

    Sam Malins

  • Contact email

    sam.malins@nottingham.ac.uk

  • Sponsor organisation

    Nottinghamshire Health care NHS Foundation trust

  • ISRCTN Number

    ISRCTN13692666

  • Duration of Study in the UK

    1 years, 6 months, 2 days

  • Research summary

    The trial seeks to evaluate the efficacy of an intervention tailored to support adult patients in cancer care awaiting psychological therapy. This intervention consists of a single remote session lasting 60-90 minutes within two weeks of referral to psychology service, followed by personalised smart messages designed to enhance motivation and behaviour change.

    Patients in cancer care are at a heightened risk of experiencing mental health challenges, including an increased risk of suicide. However, these difficulties often go unnoticed, impacting both their quality of life and the effectiveness of cancer treatment. Currently, the wait time for psychological therapy ranges from four to ten weeks, during which symptoms may exacerbate. Moreover, engaging in therapy poses additional challenges, given patients' numerous commitments, necessitating an effective approach to maximise therapy benefits. Research suggests that a brief preparatory intervention can improve therapy outcomes, particularly when combined with technological support.

    This proposed intervention, blending a single preparatory session with smart messaging, offers a cost-effective, easily implementable solution to enhance clinical outcomes and mental well-being amongst cancer patients. We aim to assess this intervention by comparing participants receiving the Therapy Preparation Intervention (TPI) alongside Treatment As Usual (TAU) with those receiving TAU alone.

    The hypotheses of the study are twofold:

    Patients receiving both TPI and TAU will experience a greater reduction in depressive symptoms compared to those receiving TAU alone.

    Patients receiving both TPI and TAU will exhibit lower dropout rates than those receiving TAU alone.

  • REC name

    London - Bromley Research Ethics Committee

  • REC reference

    24/LO/0610

  • Date of REC Opinion

    26 Sep 2024

  • REC opinion

    Further Information Favourable Opinion